Lilly’s Oral GLP-1, Orforglipron, Delivers Weight Loss Of Up To An Average Of 27.3 Pounds In Adults With Obesity

Adults who participated in a clinical trial of an oral glucagon-like peptide-1 (GLP-1) medication called orforglipron (pronounced “or-for-GLIP-ron”) developed by Eli Lilly and Company for weight loss lost about 12.4% of their body weight after 72 weeks, with average weight loss of 27.3 pounds, according to a recent announcement by the company. The Phase 3 ATTAIN-1 trial evaluated the oral medication at three dosing levels (6 mg, 12 mg, and 36 mg) compared to a placebo, and all participants adopted a healthy diet and physical activity. Lilly is developing the oral . . .